# US 2006/0051347 A1 · Process for concentration of antibodies and therapeutic products thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051347 A1
- Document ID: US20060051347A1
- Status: Published application
- Kind: A1
- Application number: 11/220,362
- Filed: 2005-09-06
- Published: 2006-03-09
- Earliest claimed: 2004-09-09
- Inventors: Charles Winter
- Web page: https://patentgrep.com/patent/US20060051347A1

## CPC

- C07K 16/4291: {against IgE}
- A61K 39/39591: {Stabilisation, fragmentation}
- B01D 61/146: {comprising multiple ultrafiltration steps}
- B01D 61/16: Feed pretreatment
- C07K 1/34: by filtration, ultrafiltration or reverse osmosis
- C07K 16/065: {Purification, fragmentation}
- B01D 2311/04: Specific process operations in the feed stream; Feed pretreatment
- B01D 2311/16: Flow or flux control
- C07K 2317/21: from primates, e.g. man
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products.

## Claims

### Claim 1

A process for preparing highly concentrated antibody compositions comprising:
a first ultrafiltering of a first antibody preparation to provide a second antibody preparation;
a diafiltering the second antibody preparation to provide a diafiltered intermediate antibody preparation; and
a second ultrafiltering of the diafiltered intermediate antibody preparation to provide a third antibody preparation;
wherein one or more of the first ultrafiltering, second ultrafiltering, and the diafiltering are accomplished at about 30° C. to about 50° C.

### Claim 2 (depends on 1)

The process of claim 1 wherein one or more of the first ultrafiltering, the second ultrafiltering, and the diafiltering are accomplished at from about 35° C. to about 50° C.

### Claim 3 (depends on 1)

The process of claim 1 wherein one or more of the first ultrafiltering, the second ultrafiltering, and the diafiltering are accomplished at from about 45° C.

### Claim 4 (depends on 1)

The process of claim 1 wherein one or more of the first ultrafiltering, the second ultrafiltering, and the diafiltering are accomplished at 45° C. plus or minus 5° C.

### Claim 5 (depends on 1)

The process of claim 1 wherein the first antibody preparation has an antibody concentration of from about 0.1 to about 10 grams per liter.

### Claim 6 (depends on 1)

The process of claim 1 wherein the first antibody preparation has an antibody concentration of about 1 to about 5 grams per liter.

### Claim 7 (depends on 1)

The process of claim 1 wherein the second antibody preparation has an antibody concentration of from about 10 to about 50 grams per liter.

### Claim 8 (depends on 1)

The process of claim 1 wherein the second antibody preparation has an antibody concentration of about 20 to about 40 grams per liter.

### Claim 9 (depends on 1)

The process of claim 1 wherein the third antibody preparation has an antibody concentration of from about 50 to about 250 grams per liter.

### Claim 10 (depends on 1)

The process of claim 1 wherein the third antibody preparation has an antibody concentration of from about 100 to about 230 grams per liter.

### Claim 11 (depends on 1)

The process of claim 1 wherein the third antibody preparation has an antibody concentration of from about 170 to about 200 grams per liter.

### Claim 12 (depends on 1)

The process of claim 1 wherein the diafiltered intermediate antibody preparation and the third antibody preparation comprise the ultra-filter retentate.

### Claim 13 (depends on 1)

The process of claim 1 wherein the intermediate antibody preparation has an antibody concentration of about 25 to about 35 grams per liter and the third antibody preparation has an antibody concentration of from about 170 to about 200 grams per liter.

### Claim 14 (depends on 1)

The process of claim 1 wherein the antibody preparation comprises anti-IgE antibodies.

### Claim 15 (depends on 1)

The process of claim 1 wherein the process is accomplished in from about 1 to 10 hours.

### Claim 16 (depends on 1)

The process of claim 1 wherein the process is accomplished in from about 2 to 5 hours.

### Claim 17 (depends on 1)

The process of claim 1 wherein the process is accomplished in about 3 hours.

### Claim 18 (depends on 1)

The process of claim 1 wherein the first and the second ultrafiltering are accomplished with an ultra-filter membrane having a nominal pore size of about 5 to about 50 kilo Daltons.

### Claim 19 (depends on 1)

The process of claim 1 wherein the first and the second ultrafiltering are accomplished with an ultra-filter membrane having a nominal pore size of about 10 to about 30 kilo Daltons.

### Claim 20 (depends on 1)

The process of claim 1 wherein the first antibody preparation contains an antibody having an apparent molecular weight of about 100 to about 200 kilo Daltons.

### Claim 21 (depends on 1)

The process of claim 1 wherein the first antibody preparation contains an antibody having an apparent molecular weight of about 150 kilo Daltons.

### Claim 22 (depends on 1)

The process of claim 1 wherein the first ultrafiltering concentrates the first antibody preparation to provide the second antibody preparation having an antibody concentration of about 30 grams per liter and the second ultrafiltering concentrates the intermediate antibody preparation to provide the third antibody preparation having an antibody concentration of about 170 to about 200 grams per liter.

### Claim 23 (depends on 1)

The process of claim 1 wherein the first ultrafiltering and the second ultrafiltering are accomplished with the same ultra-filter membrane.

### Claim 24 (depends on 1)

The process of claim 1 wherein the first ultrafiltering and the second ultrafiltering are accomplished with a regenerated cellulose composite ultra-filter membrane.

### Claim 25 (depends on 1)

The process of claim 1 wherein the diafiltering accomplishes a buffer exchange at constant volume, constant concentration, or both.

### Claim 26 (depends on 1)

The process of claim 1 wherein the diafiltering accomplishes a buffer exchange of from about 5 to about 15 fold volumes.

### Claim 27 (depends on 1)

The process of claim 1 wherein the diafiltering accomplishes a buffer exchange of from about 8 fold volumes.

### Claim 28 (depends on 1)

The process of claim 1 wherein the diafiltering exchanges a first buffer for a second buffer.

### Claim 29 (depends on 28)

The process of claim 28 wherein the first buffer comprises a mixture of aqueous sodium chloride and a TRIS buffer, and the second buffer comprises a mixture of aqueous histidine chloride and arginine chloride.

### Claim 30 (depends on 1)

The process of claim 1 wherein the first ultrafiltering, the second ultrafiltering, and the diafiltering are accomplished with tangential flow filtration across an ultra-filter membrane.

### Claim 31 (depends on 1)

The process of claim 1 wherein the first ultrafiltering, the second ultrafiltering, and the diafiltering are accomplished with tangential flow filtration across the same ultra-filter membrane.

### Claim 32 (depends on 1)

The process of claim 1 wherein the yield of the third antibody preparation is greater than about 70 weight % based on the weight of antibodies in the first antibody preparation.

### Claim 33 (depends on 32)

The process of claim 32 wherein the yield of the third antibody preparation is from about 80 to about 100 weight % based on the weight of antibodies in the first antibody preparation.

### Claim 34 (depends on 1)

The process of claim 1 wherein the first ultrafiltering has a recirculation rate of from about 0.5 L/min/ft2 to about 5 L/min/ft2.

### Claim 35 (depends on 1)

The process of claim 1 wherein the ultrafiltering and diafiltering are accomplished at a transmembrane pressure of from about 10 to about 50 p.s.i.

### Claim 36 (depends on 1)

The process of claim 1 wherein there is provided an antibody concentrate with a detectable bio-burden of less than about 100 CFU/mL.

### Claim 37

A process for concentrating proteins comprising:
a first ultrafiltering of a first protein mixture to provide a second protein mixture;
a diafiltering of the second protein mixture to provide a diafiltered protein mixture; and
a second ultrafiltering of the diafiltered protein mixture to provide a third protein mixture, wherein one or more of the first ultrafiltering, the diafiltering, and the second ultrafiltering are accomplished at from about 30° C. to about 50° C.
